Bavarian Nordic

Bavarian Nordic

Bavarian Nordic

Bavarian Nordic (OMX:$BAVA, OTC:$BVNRY) develops cancer immunotherapies and vaccines against infectious diseases
Raised
$105.9M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$50,000,000
Post-IPO debt - 2015
European Investment Bank (EIB)
$55,874,661
Post-IPO debt - 2015
European Investment Bank (EIB)
Team Size
1–10
Employees
Location
Headquarters
$50,000,000 Post-IPO debt
BioPortfolio

Bavarian Nordic Granted EUR 50 Million Loan from The European Investment Bank